Ten years ago, a medical affairs strategy could live quietly inside a launch plan. In 2026 it can't. Payers demand evidence before they'll listen, HCPs split their attention between congresses and digital channels, and leadership expects medical affairs to show impact in numbers — not anecdotes. The teams thriving in this environment aren't the biggest ones; they're the ones with a strategy specific enough to say no to things.
This guide walks through how to build that strategy: the framework, a working template you can copy, the KPIs that prove impact, and the traps that sink most plans by Q3.
What is a medical affairs strategy? A medical affairs strategy is the plan that defines how a life sciences company generates, communicates, and measures scientific value across a product's lifecycle — covering evidence generation, KOL and stakeholder engagement, medical communication, and field medical execution. A strong strategy ties each activity to measurable objectives and to the questions HCPs, payers, and regulators are actually asking.
Medical affairs sits between R&D, commercial, and the outside scientific world — close enough to each to translate, independent enough to stay credible. That position is why its remit keeps expanding: across the industry, the function is increasingly treated as a third strategic pillar alongside R&D and commercial, accountable for patient impact rather than activity counts.
In practice, the modern medical affairs function owns four jobs: generating and shaping evidence (including real-world evidence), engaging KOLs and emerging digital opinion leaders, answering the field's scientific questions compliantly, and feeding what the field learns back into strategy. The strategy document is what keeps those four jobs pointed at the same goals.
The framework below aligns with the structure the Medical Affairs Professional Society (MAPS) recommends for a medical strategic plan: situation analysis first, objectives before tactics, measurement built in from day one.
Start with gaps, not activities: where does the scientific community misunderstand the disease state or the data? What do HCPs ask most often? Which unmet patient needs does your evidence actually address? Pull from advisory boards, field medical insights, medical information request patterns, and publication landscape analysis. If your MIR log shows the same off-label question arriving weekly, that's a needs assessment finding — not an inbox nuisance.
Anchor objectives to lifecycle phase: pre-launch is about disease-state education and evidence readiness; launch is about scientific adoption and formulary conversations; post-launch is about RWE dissemination and lifecycle expansion. Each objective needs a number and a date — “increase Tier-1 KOL engagement depth” is a wish; “complete engagement plans with 90% of Tier-1 KOLs by end of Q2” is an objective.
Build a stakeholder map that spans traditional KOLs, rising researchers, DOLs, patient advocacy groups, and payer-side clinical voices. Tier them by scientific influence and strategic relevance — then let the tiers drive resourcing. Modern KOL identification tooling uses publications, trial activity, conference presence, and digital footprint to keep the map current instead of frozen at last year's advisory board list.
Plan the evidence portfolio deliberately: which gaps get an RCT sub-analysis, which get an RWE study, which get a registry or investigator-initiated trial. Sequence it against the payer calendar — the formulary review that happens eight months after launch is won by evidence commissioned two years before it. Then plan distribution with the same rigor: target journals ranked by audience rather than prestige alone, a congress calendar mapped to abstract deadlines, and plain-language summaries for the audiences journals never reach. Evidence nobody encounters changes nothing.
The strategy fails if execution data lives in spreadsheets. A purpose-built medical affairs CRM ties KOL engagement plans, field insight capture, MIR routing, and conference planning to the objectives you set in step two — so mid-year review is a dashboard read, not an archaeology project.
Set a quarterly strategy review with real data: KPI trends, insight themes, competitive and regulatory shifts. The plan you write in January should be visibly smarter by July — if it hasn't changed at all, it isn't being used.
Steps 3, 5, and 6 are where most strategies stall — see how medical affairs teams run stakeholder maps, insight capture, and KPI dashboards in one platform.
Book a 20-minute walkthroughUse this one-page structure as the skeleton of your medical strategic plan. It mirrors how successful plans are organized and gives every function — field medical, medical information, publications, HEOR — a place to see itself:
1. Situation analysis — disease-state landscape, evidence gaps, competitive scientific position, stakeholder sentiment.
2. Strategic imperatives (3–5 max) — the few things that must be true by year end; each mapped to a lifecycle phase.
3. Objectives & KPIs — one measurable objective per imperative, with baseline, target, and owner.
4. Stakeholder plan — tiered KOL/DOL map, engagement cadence per tier, advisory board calendar.
5. Evidence & publication plan — studies, RWE projects, publication targets, congress calendar.
6. Field medical plan — MSL territory priorities, insight themes to probe, MIR readiness.
7. Enablement — technology, training, budget, compliance guardrails.
8. Review cadence — quarterly checkpoints, KPI dashboard owner, criteria for mid-year re-planning.
Two rules make the template work: no imperative without a KPI, and no activity that doesn't ladder to an imperative. Everything else is formatting.
Engagement depth beats contact frequency. A Tier-1 KOL with a genuine research collaboration moves science; the same KOL with twelve check-in emails moves nothing. Build each priority relationship around a bespoke plan — scientific interests, preferred channels, collaboration opportunities — and track it in your KOL engagement system so continuity survives MSL turnover.
Extend the same discipline to DOLs and patient advocates. Their influence operates on different timescales (a post circulates in days; a publication in months), so engagement cadence and content have to differ too.
Data doesn't persuade by itself — relevance does. Work with HEOR to translate outcomes into the economic terms payers use, and into patient-level narratives HCPs remember after clinic hours. The same trial result becomes three artifacts: a payer dossier input, a congress presentation, and a plain-language summary. Teams that pre-plan all three per study get triple the mileage from every evidence dollar.
Pick a handful per objective — a wall of forty metrics is how impact hides. The ones that consistently earn leadership attention:
For a deeper treatment, see our guide to optimizing medical affairs KPI tracking.
A global medical affairs strategy sets the scientific narrative, evidence priorities, and KPI definitions once — then gives regions room to localize stakeholder plans and channel mix. The failure mode is well known: global writes a beautiful deck, affiliates quietly run last year's plan. The fix is structural, not motivational: shared insight taxonomy, one KPI dashboard across regions, and quarterly global-affiliate reviews where field data — not slideware — drives the agenda.
Digital isn't a separate strategy; it's the medium most of your strategy now travels through. Four areas deserve explicit treatment in the plan:
The unifying requirement is data discipline: every digital touchpoint should write back to the same system your MSLs use, or the omnichannel picture fragments into channel silos and the insights loop breaks.
Compliance isn't a section of the strategy; it's the foundation under all of it. Scientific exchange must stay clearly separated from promotion, MIR handling needs audit-ready documentation, and engagement with HCPs must respect regional codes (PhRMA Code, EFPIA, Sunshine Act reporting). Build the guardrails into workflows — approved content libraries, documented interaction types, compliant MIR routing — so the field never has to improvise a judgment call at a congress booth.
A medical affairs strategy is a documented plan defining how a company generates scientific evidence, engages KOLs and stakeholders, communicates medical value, and measures impact across a product's lifecycle. It aligns field medical, medical information, publications, and HEOR behind shared, measurable objectives.
Eight components: situation analysis, 3–5 strategic imperatives, measurable objectives with KPIs, a tiered stakeholder plan, an evidence and publication plan, a field medical plan, enablement (technology, training, budget), and a defined review cadence. The template above expands each.
Commercial strategy drives prescribing and revenue through promotion; medical affairs strategy drives scientific understanding through compliant, non-promotional exchange. They inform each other — medical insights shape commercial planning — but they run on separate objectives, separate metrics, and strict compliance boundaries.
Through KPIs set at planning time: KOL engagement plan completion, insight volume and insight-to-action rate, publication plan adherence, MIR turnaround, and scientific share of voice. The discipline is choosing a few per objective and reviewing them quarterly against baselines.
Review quarterly, re-plan annually — and re-plan immediately on trigger events: new pivotal data (yours or a competitor's), a regulatory shift, or a launch timeline change. A strategy that survives twelve months untouched usually isn't being consulted.
The head of medical affairs owns the plan; function leads (field medical, medical information, publications, HEOR) own their sections and the KPIs attached to them. Every imperative needs one named owner — shared ownership is the most reliable way for a strategic imperative to go unexecuted.
A successful medical affairs strategy in 2026 isn't a longer document — it's a tighter one: a handful of imperatives, each with a number attached, a stakeholder map that reflects where influence actually lives, and a review rhythm that turns field intelligence into course corrections. Write it so that in December you can say, in numbers, what changed because your team existed. That's the version leadership funds again.
See how medical affairs teams run this entire playbook — KOL plans, insights, MIRs, and KPI dashboards — in TikaMSL.
Book a 20-minute walkthrough